

**Teriparatide (Forsteo<sup>®</sup>)**

**(No. 71/03)**

**Eli Lilly**

## **Summary of Recommendation**

8 December, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**Advice:** following a full submission.

Teriparatide (Forsteo<sup>®</sup>) is accepted for restricted use within NHS Scotland for the treatment of established (severe) osteoporosis in post-menopausal women.

This medicine should be restricted to initiation by specialists experienced in the treatment of osteoporosis following assessment of fracture risk including measurement of BMD. It is the first product to be licensed specifically for established (severe) post-menopausal osteoporosis. It has shown efficacy in reducing vertebral and non-vertebral fractures in post-menopausal women with prior vertebral fractures, particularly in a sub-group with documented severe osteoporosis. At the recommended daily dose it is expensive but appears to be cost-effective in women with proven osteoporosis who have developed fractures.

Professor David H Lawson  
Chairman